A section of Journal of Functional Biomaterials (ISSN 2079-4983).
The section is devoted to the dissemination of knowledge relating to studies of or including antibacterial and antifungal agents. Antimicrobial activity is broadly described as a material's capacity to prevent or mitigate microbial growth, reduce their number, or directly kill the microbes. Manuscripts should describe the synthesis, characterization, and applications of antimicrobial compounds that target human infectious diseases. Moreover, the top ten antibiotic pathogens (https://www.drugs.com/article/antibiotic-resistance.html), food and water-borne bacteria, considering frequent catheter-related bloodstream and urinary catheter infections, target pathogens include (but not exclusively) S. aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Enterococci, Klebsiella pneumoniae, Proteus mirabilis, and yeasts (Candida albicans). Other target pathogens are bacteria and fungi that cause prosthetic joint infections, oral cavity, and infections of acrylic dentures. Other yeasts of interest are C. gatti, C. neoformans, C. auris, etc.
The section welcomes the submission of papers to unravel the synthesis and application of novel biomaterials (peptides, proteins, biopolymers, etc.) with antimicrobial activities. Studies of novel antimicrobials must provide some data showing the potential intended applications. Basic requirements include MIC studies, solubility, protein binding, and tolerability (mammalian cell toxicity). Concerning biocompatibility, priority is given to antimicrobials with target-specific mechanisms of microbial cells but not of mammalian cells. Analytical chemistry data (NMR, FTIR, Raman, etc.) used to verify the structure and purity of novel antimicrobial compounds should be included as supplementary material.
Papers with conventional biomaterials are only encouraged for submission if they provide emerging applications or solid antimicrobial mechanisms to elucidate the physiological effects of antimicrobials as supported by microscopic and/or spectroscopic evidence. Similarly, papers based on conventional biomaterials such as chitosan, poly‐ε‐lysine, polyethylenimine, polyguanidine, alginate, starch-based polymers, etc. are not considered unless they are functionalized with quaternary ammonium compounds, antibiotics (beta-lactams, fluoroquinolones, glycopeptides, aminoglycosides, etc.), N-halamines, N-chloramines, and other biomolecules. The invitation for submission is also extended to physical and chemical methods that can modify the surface properties of conventional or novel biomaterials.
Conducting polymers or other synthesized polymers must be functionalized with biomolecules as antimicrobial moieties. The section is also opens submissions that advocate the development of nanocomposites of biomaterials with nanoparticles (metal oxides, metals, and non-metals) and carbon dots.
Of interest are studies involving the destruction of biofilms by antimicrobials as well as the techniques for probing biofilm morphology (porosity, surface roughness, and film thickness) and chemical compositions.
Following special issues within this section are currently open for submissions:
- Antibacterial Biomaterials (Deadline: 20 September 2022)
- Functional Biomaterials and Biomaterial Composites with Antimicrobial Properties (Deadline: 15 October 2022)
- Assays for the Impact of Functional Biomaterials on Cell Proliferation, Cell Viability, and Cell Metabolic Activities (Deadline: 20 November 2022)